Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
US Army
Argus Health

Generated: September 19, 2019

DrugPatentWatch Database Preview

Patent: 6,217,866

  Try a free trial

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,217,866
Title: Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
Abstract:Hybridoma cell lines producing monoclonal antibodies specific to the human epidermal growth factor receptor are disclosed. The antibodies are capable of inhibiting the growth of human tumor cells expressing human epidermal growth factor receptors. Therapeutic uses of these monoclonal antibodies by themselves and in combination with anti-neoplastic agents are also disclosed.
Inventor(s): Schlessinger; Joseph (New York, NY), Givol; David (Rehovot, IL), Bellot; Francoise (Fresnes, FR), Kris; Richard (Tucson, AZ), Ricca; George A. (Blue Bell, PA), Cheadle; Christopher (West Chester, PA), South; Victoria J. (Audubon, PA)
Assignee: Rhone-Poulenc Rorer International (Holdings), Inc. (Greenville, DE)
Application Number:08/487,761
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,217,866
Patent Claims:see list of patent claims

Details for Patent 6,217,866

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Imclone ERBITUX cetuximab VIAL; INTRAVENOUS 125084 001 2004-06-18 ➤ Sign Up Rhone-Poulenc Rorer International (Holdings), Inc. (Greenville, DE) 2018-04-17 RX Orphan company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Johnson and Johnson
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.